×

Cesca Therapeutics to Announce First Quarter Fiscal 2016 Results on November 16, 2015

RANCHO CORDOVA, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, announced today it will report financial results for the fiscal first quarter ended September 30, 2015, on Monday, November 16, 2015.

Company's Conference Call and Webcast

Management will host a conference call Monday, November 16, 2015 at 2:00 PM Pacific (5:00 PM Eastern) to review the fiscal first quarter financial results.

The call can be accessed by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing, "Cesca." Mr. Robin Stracey, Chief Executive Officer and Mr. Michael Bruch, Chief Financial Officer will be on the call to discuss the first quarter results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately five minutes before the conference call begins.

To listen to the audio webcast of the call during or after the event, please visit: http://cescatherapeutics.com/investors/webcasts-calls/.

Replay

A replay of the conference call will be available two hours after the call for the following five business days by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and entering the following account number when prompted: '10076095'.

About Cesca Therapeutics Inc.

Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.

CONTACT: Cesca Therapeutics Inc. http://www.cescatherapeutics.com Investor Contact: Kirin Smith, PCG Advisory Group 646-863-6519, or ir@cescatherapeutics.com Media Contact: Sean Leous, PCG Advisory Group 646-863-8998 or sleous@pcgadvisory.com

Source:Cesca Therapeutics Inc.